Paradigm BioCapital Advisors LP (“PBCA”, the “Firm” or the “Investment Manager”) is a
Delaware limited partnership that was formed in July 2020. The general partner of PBCA is Paradigm
BioCapital Advisors GP LLC (“PBCAGP”). Dr. Senai Asefaw (the “Principal”) is the managing
member and principal owner of PBCAGP.
PBCA provides investment advisory services to private funds via a master-feeder structure, whereby
Paradigm BioCapital Partners Fund, LP (the “Domestic Fund”), a Delaware limited partnership, and
Paradigm BioCapital Partners Fund, Ltd. (the “Offshore Fund”) a Cayman Islands exempted company
together with the Onshore Fund, the “Feeder Funds”, invest substantially all of their assets in
Paradigm BioCapital International Fund Ltd. (the “Master Fund”), a Cayman Islands exempted
company. Unless otherwise specified, the Domestic Fund, the Offshore Fund and the Master Fund are
each referred to as a “Fund” and collectively, as the “Funds”. Additionally, PBCA manages one
separately managed account on a discretionary basis pursuant to an Investment Management
Agreement with the underlying investor (the “SMA”).
Hereinafter, where applicable, the Funds and the SMA are collectively referred to as the “Clients”.
PBCA manages the Funds pursuant to investment guidelines set forth in the relevant governing and
offering documents of the Funds, including any limited partnership agreement, investment management
agreement, private placement memorandum and/or subscription agreement (each an “Offering
Document”, and collectively, the “Offering Documents”). The Offering Documents contain more
detailed information about the Funds, including a description of the investment objective and strategy
or strategies employed by the Funds and related restrictions that serve as a limitation on PBCA’s
advice or management.
PBCA will not tailor its advisory services to the individual investors in the Funds (each an “Investor”
and
collectively the “Investors”), or provide Investors with the right to specify, or restrict the Funds’
investment objectives or any investment or trading decisions. Accordingly, an investment in a Fund
does not create a client-adviser relationship between such Investors and PBCA. Each of the Funds are
expected to rely on the exception from the definition of an “investment company” provided by Section
3(c)(7) of the U.S. Investment Company Act of 1940, as amended (the “1940 Act”). Each Investor is
strongly encouraged to undertake appropriate due diligence, including but not limited to a review of
relevant Offering Documents and the additional details about PBCA’s investment strategies, methods
of analysis and related risks (as discussed in Item 8 of this Brochure and each Fund’s Offering
Documents) in considering whether PBCA’s advisory services, or an investment in a Fund are
appropriate to its own circumstances, based on all relevant factors including, but not limited to, the
Investor’s own investment objectives, liquidity requirements, tax situation and risk tolerance before
making an investment decision.
The general partner of the Onshore Fund and Master Fund is Paradigm BioCapital GP LLC (the
“General Partner”), a Delaware limited liability company. The General Partner has ultimate
responsibility for decisions relating to management and operations made on behalf of the Domestic
Fund and the Master Fund and has ultimate responsibility for the investment decisions made on behalf
of the Master Fund but has delegated certain responsibilities to PBCA.
Additional detailed information about PBCA is provided below, including information about PBCA’s
advisory services, investment approach, personnel and affiliations.
PBCA does not participate in wrap fee programs.
PBCA currently provides discretionary investment advisory services to the Clients with a total of
$2,358,206,292 in regulatory assets under management.